Lexatumumab
Based on 1 Customer Validation
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 845816-02-6
- Molecular Weight:143.48 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 lambda2
Human
TNFRSF10B/TRAILR2/CD262
The combination of Cisplatin (HY-17394) with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death[1].
Lexatumumab (0-10 µg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Melanoma cell lines
-
Concentration:0.01, 0.1, 1.0 and 10.0 µg/ml
-
Incubation Time:72 h
-
Result:Induced various degrees of cell death in the different cell lines.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:FEMX-1 xenografts mice[2]
-
Dosage:10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)
-
Administration:i.v., twice a week
-
Result:Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
-
Immobilized Human DR5/TRAIL R2 Protein (His Tag) can bind Lexatumumab. The EC50 for this effect is 1.14 ng/mL. -
Flow cytometric analysis of 1.5X106 HEPG2 cells with Lexatumumab (HY-P99299, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda2, Isotype Control (HY-P990096, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 845816-02-6
-
Appearance Liquid
-
Molecular Weight 143.48 kDa
-
Color Colorless to light yellow
-
SMILES
[Lexatumumab]
-
Synonyms
HGS-ETR 2; ETR2-ST01
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66. [Content Brief]
[2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lexatumumab Related Classifications
HY-P99299 Related Classifications
Powered by Bioz